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Abstract 
Progressive external ophthalmoplegia is typically associated with single or multiple mtDNA deletions but occasionally mtDNA single 
nucleotide variants within mitochondrial transfer RNAs (mt-tRNAs) are identified. We report a 34-year-old female sporadic patient with 
progressive external ophthalmoplegia accompanied by exercise intolerance but neither fixed weakness nor multisystemic involvement. 
Histopathologically, abundant COX-deficient fibres were present in muscle with immunofluorescence analysis confirming the loss of 
mitochondrial complex I and IV proteins. Molecular genetic analysis identified a rare heteroplasmic m.15990C > T mt-tRNA Pro variant reported 
previously in a single patient with childhood-onset myopathy. The variant in our patient was restricted to muscle. Single muscle fibre analysis 
identified higher heteroplasmy load in COX-deficient fibres than COX-normal fibres, confirming segregation of high heteroplasmic load with 
a biochemical defect. Our case highlights the phenotypic variability typically observed with pathogenic mt-tRNA mutations, whilst the 
identification of a second case with the m.15990C > T mutation not only confirms pathogenicity but shows that de novo mt-tRNA point 
mutations can arise in multiple, unrelated patients. 
© 2020 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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(. Introduction 
Mitochondrial diseases are a group of inherited, metabolic
isorders with heterogeneous, systemic or organ-specific 
ymptoms, often showing poor phenotype–genotype 
orrelation. As a direct consequence, the presence of
eterogeneous clinical symptoms associated with a unique∗ Corresponding author. PD Dr. Pushpa Raj Joshi, Department of 
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( mt-tRNA Pro ) gene variant, Neuromuscular Disorders, https:// doi.org/ 10.1016/ j.nmenetic variant is a classical trait of mitochondrial disorders
1] . Progressive external ophthalmoplegia (PEO) is a common
itochondrial clinical feature that presents with gradually
orsening bilateral ptosis and ophthalmoparesis. PEO may
e present as the sole clinical feature or can be associated
ith multisystemic disease presentations. Single, large-scale 
tDNA deletions or nuclear gene defects associated with
isordered mtDNA maintenance resulting in multiple mtDNA
eletions are frequently associated with PEO [2 , 3] . In
ddition, mtDNA point mutations are also detected in a small
roportion of PEO patients; the m.3243A > G mutation is
he most frequently identified mitochondrial point mutation
n patients with PEO [3] , although more than 30 differentss article under the CC BY-NC-ND license. 
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Fig. 1. Clinical photography of the eyes of the patient (aged 35 years) 
showing bilateral ptosis, affecting the right eye more than the left. 
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t  point mutations are reported ( https:// www.mitomap.org/ ).
These can be inherited or somatic and are almost exclusively
localized in mitochondrial (mt-) tRNA genes [4 , 5] . 
Here we present a case of adult-onset progressive external
ophthalmoplegia (PEO) due to a m.15990C > T MT-TP variant
that was previously identified in a child with isolated
myopathy, demonstrating firm evidence of pathogenicity. 
2. Case report 
A 34-year-old woman originally from Kosovo presented
with an 8-month history of ptosis of the right eye. She
complained of ocular pain and watery eyes with increased
glare sensitivity without double vision. Dysphagia and
dysarthria were denied. The patient later developed myalgia
and exercise intolerance involving mainly her proximal
limbs. Family history for neuromuscular disorders, especially
ptosis or muscle symptoms, was negative. The patient’s
father died of a stroke; her mother, nine siblings and two
children aged 7 and 9 years are all clinically asymptomatic.
At age 35 years, she had a miscarriage after 3 months
of pregnancy. Neurological examination showed a right
greater than left ptosis and a mild ophthalmoparesis in
all directions with particularly limited amplitude of upgaze
( Fig. 1 ). Further neurological examination was normal. In
particular, there was no evidence for bulbofacial/ limb muscle
weakness or neuropathy. Encephalopathic symptoms such
as cognitive impairment, epileptic seizures and cerebellar
signs were not present. Laboratory testing revealed normal
values for blood lactate but level of creatine kinase
(CK) was increased 3 to 5 times the upper limit of
normal. Electromyography (EMG) was normal. Cardiological
examinations, including echocardiogram (ECG, long-term
ECG) and echocardiography revealed no abnormalities. An
ophthalmological examination did not show signs of a
retinopathy. Furthermore, MRI imaging of the brain, EEG
and audiometry results were normal. 
Clinical examination suggested PEO and hence, an open
muscle biopsy of the deltoid muscle was performed and
processed according to standard procedures. Written consent
was obtained from the patient for further histological,
biochemical and molecular investigations. Standard histology
[hematoxylin and eosin (H&E)] and oxidative enzyme
histochemistry [cytochrome c oxidase (COX), succinate
dehydrogenase (SDH) and sequential COX/SDH activities]
were performed on 10 μm transversely-orientated frozen
skeletal muscle sections as described previously [6] . These
Please cite this article as: P.R. Joshi, K. Baty and S. Hopton et al., Progressive 
( mt-tRNA Pro ) gene variant, Neuromuscular Disorders, https:// doi.org/ 10.1016/ j.nmistological analyses revealed well-preserved activity of
uccinate dehydrogenase (SDH) throughout the biopsy.
owever, both the individual COX and sequential COX/SDH
istochemical reactions showed extensive COX-deficiency
75% COX-deficient fibres) ( Fig. 2 A). Based on these
ndings, a quantitative, quadruple immunofluorescence
nalysis was performed to interrogate NDUFB8 (complex
) and COXI (complex IV) immunoreactivities [7] that
onfirmed a mitochondrial defect involving loss of both
omplex I and complex IV proteins ( Fig. 2 B). 
For molecular genetic analysis, total DNA of the patient
as extracted from available tissues (muscle, blood, urothelial
ells, buccal cells and hair shafts) following standard
rocedures. Total DNA of her mother was also extracted
rom blood, urothelial cells, buccal cells and hair shafts.
enetic testing of two clinically-asymptomatic children was
ot performed due to ethical reasons. Asymptomatic siblings
ere not available for clinical and genetic investigations.
ong range PCR of muscle DNA [8 , 9] of the patient did
ot identify large scale deletions. A panel of 11 nuclear
enes responsible for Mendelian PEO ( SPG7, TWNK, TK2,
GME1, RNASEH1, CHRNE, C12orf65, DGUOK, DNM2,
YMP and POLG ) was tested but no pathogenic variants
ere identified. As a consequence, the entire mitochondrial
enome of the patient was sequenced using DNA extracted
rom muscle using previously described protocols [9] . This
dentified a heteroplasmic mt-tRNA Pro variant, m.15990C > T,
resent at high levels. Quantitative pyrosquencing was
erformed as previously described [10 , 11] , revealing a
eteroplasmy level of 78% in muscle. However, the
.15990C > T variant could not be detected in DNA extracted
rom blood, urothelial cells, buccal cells and hair shafts
btained from either the patient or her mother. Furthermore,
nalysis of individual COX-deficient and COX-positive fibres
sing pyrosequencing following laser-capture microdissection
etected a statistically-significantly higher mutation load in
OX-deficient fibres [89.75 ±6.84 ( n = 20)] than in COX-
ositive fibres [14.00 ±6.84 ( n = 17)] ( p < 0.001) ( Fig. 2 C),
hus confirming causality. 
. Discussion 
We present a case of mitochondrial PEO, where
he identification of a rare mt-tRNA Pro gene variant -
.15990C > T - supported the clinical and histopathological
ndings in our patient’s muscle biopsy. This rare mtDNA
ariant was reported previously on one occasion, more
han 25 years ago, in single case of a 9-year old US-
merican Caucasian girl with a generalized myopathy and
actic acidosis since age 7-years without PEO [12] . Family
istory for neuromuscular disorders was negative. Similar
o our patient, the mutation was also restricted to skeletal
uscle with a heteroplasmy level of 85%. The variant is
isted as possibly pathogenic with a pathogenicity score of
nly 51.7% ( https:// www.mitomap.org/ ). The pathogenicity
core of this variant was calculated using mitochondrial
RNA informatics predictor (MitoTIP) scoring system [13] .external ophthalmoplegia due to a recurrent de novo m.15990C > T MT-TP 
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Fig. 2. Histopathological evaluation of skeletal muscle . ( A ) Histological and histochemical analyses of the patient’s skeletal muscle biopsy showing 
hematoxylin and eosin (H&E) staining (i), cytochrome c oxidase (COX) histochemistry (ii), succinate dehydrogenase (SDH) histochemistry (iii) and sequential 
COX/SDH histochemistry (iv), highlighting the marked COX defect; scale bar = 100 μm. ( B ) Quadruple immunofluorescence analysis of NDUFB8 (complex I) 
and COXI (complex IV) mitochondrial subunits depicting loss of complex I (NDUFB8) and complex IV (COX I) proteins. Each dot represents the measurement 
from an individual muscle fibre, colour co-ordinated according to its mitochondrial mass (low = blue, normal = beige, high = orange, very high = red). grey dashed 
lines represent SD limits for classification of the fibres. Lines next to x- and y-axes represent the levels of NDUFB8 and COXI: beige = normal ( > −3), light 
beige = intermediate positive ( −3 to −4.5), light purple = intermediate negative ( −4.5 to −6), purple = deficient ( < −6). Bold dashed lines represent the mean 
expression level of normal fibres. 
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ghis method uses commonly accepted criteria for pathogenic
tDNA variants such as available databases of benign
nd pathogenic variants, alignment between diverse tRNAs,
tructural information and comparative genomics to predict
he impact of all possible single-base variants and deletions.
ssigning clear pathogenicity to mt-tRNA variants is very
mportant as their causative role in mitochondrial diseases
ave been clearly established [14] . In the present report,
e were able to assign pathogenicity to this m.15990C > T
ase substitution based on a validated pathogenicity scoring
ystem that uses more standard tools such as biochemical and
olecular genetic findings to assign pathogenicity [15] . With
 total score of 15 out of 20 points, this substitution clearly
xceeded the suggested threshold of 11 points to judge a
ariant as definitively pathogenic. In addition to the functional
riteria used in this scoring system, the pathogenicity of this
utation is strongly established due to its location within the
ighly evolutionary-conserved and critical anticodon domain 
f the mt-tRNA Pro ( Fig. 3 A & B). So far, 7 pathogenic
ariants (MitoTIP possibly, likely or confirmed) in mt-tRNA
nticodon loops are known (5 of those variants resulting
n anticodon swaps) amongst a total of 157 pathogenic
possibly, likely, or confirmed) mt-tRNA variants ( https:// 
ww.mitomap.org/; website accessed on 10.02.2020). The 
eported pathogenic variants in mt-tRNA anticodon loops are
isted in supplemental Table S1. 
A calculation based on a ratio of possibly, likely
r confirmed pathogenic variants to mt-DNA nucleotidesPlease cite this article as: P.R. Joshi, K. Baty and S. Hopton et al., Progressive 
( mt-tRNA Pro ) gene variant, Neuromuscular Disorders, https:// doi.org/ 10.1016/ j.nmeveals 4.6% in the mt-anticodon loops (7 variants in 154
ucleotides) and 7.6% resulting in anticodon swaps (5 variants
n 66 nucleotides) compared to 11% besides anticodon
oops (150 variants in 1355 nucleotides). This suggests
hat the anticodon loop is not a particular hot-spot for
athogenic mt-tRNA variants. A possible explanation could
e that most anticodon changes would act in a dominant
ashion, resulting in lethal mutations, even when present at
ow levels [12] . Moreover, mt-anticodon swap variants are
elieved to contribute to high fidelity of codon recognition,
he structural formation and stabilization of functional
t-tRNAs [16] . 
Absence of detectable levels of the pathogenic variant in
ther tissues apart from muscle and asymptomatic status of
he mother and 9 siblings strengthen de novo occurrence
f the mutation in our patient. This is strongly supported
y the fact that the reported variant was not detected in
ifferent tissues of the mother. De novo point mutations are
ommon in mitochondrial disease and in spite of the strict
aternal inheritance of many mtDNA point mutations, de
ovo point mutations have a low risk of recurrence [17] .
owever, identification of the m.15990C > T variant in a
econd independent sporadic case shows that recurrence of
e-novo pathogenic mtDNA variants can occur in independent
amilies. This was previously observed in patients with
he m.10191T > C variant located in a protein coding gene
complex I subunit) [18] but not in patients with mt-tRNA
ene mutations. external ophthalmoplegia due to a recurrent de novo m.15990C > T MT-TP 
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Fig. 3. Mitochondrial DNA studies reveal a pathogenic m.15990C > T variant that affects an evolutionary conserved residue and base pair within the anticodon 
loop of the MT-TP gene. ( A ) Schematic representation of the mt-RNA Pro cloverleaf structure, highlighting the position of the pathogenic m.15990C > T variant. 
( B ) Multiple sequence alignment highlighting the evolutionary conservation of the affected nucleotide at this position (denoted by an asterisk). ( C ) Single 
fibre PCR analysis showing definitive segregation of the m.15990C > T variant with a biochemical defect in individual COX-deficient muscle fibres. 
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H  The risk of transmission to offspring of pathogenic
mt-tRNA mutations is found to be very high only when the
mutation is present, to some extent, in rapidly replicating
tissue such as blood [19] . The identified mutation in our
patient was restricted only to muscle, as it could not be
identified in the DNA of other tissues, including blood,
urothelial cells, buccal cells and hair shaft predicting a very
low probability of transmission of this mutation to offspring.
Hence, the recent miscarriage that our patient suffered with
might not be as a consequence of the pathogenic mtDNA
variant she harbors. The fact that the patient had no extra-
muscular symptoms and clinically asymptomatic status of
both her children suggest that this variant might result
due to somatic mosaicism, in which other tissues besides
muscle are spared. Somatic mtDNA point mutations seem
to occur early in life due to mtDNA replication errors
and/or spontaneous cytosine deamination and clonally expand
throughout adulthood [20] . Our strong feeling however is that
the mutation occurs a de novo mutational event, present only
in the patient’s muscle, and that her miscarriage is not related
to the m.15990C > T variant. 
Identification of the m.15990C > T variant only in muscle
strengthens the significance of genetic testing of suspected
mitochondrial patients in skeletal muscle despite the high
sensitivity of the current NGS-based mtDNA screening
techniques [19 , 21] . To date, 13 different pathogenic point
mutations are reported in mt-tRNA Pro gene ( https://www. t  
Please cite this article as: P.R. Joshi, K. Baty and S. Hopton et al., Progressive 
( mt-tRNA Pro ) gene variant, Neuromuscular Disorders, https:// doi.org/ 10.1016/ j.nmitomap.org/). The phenotypes associated with these reported
ariants are heterogeneous, including a pure myopathy
12 , 21] , symptoms related to Parkinson disease [22] ,
ultisystem disorders preferentially affecting the proximal
uscle and nervous system (mitochondrial cytopathy) [23 , 24] ,
ilated cardiomyopathy [25] and MERRF-like syndromes
14] . The m.15990C > T variant found in our patient thus
xtends the clinical spectrum of mt-tRNA Pro gene defects
nd strengthens the notion that a single, pathogenic mt-tRNA
ene variant can result in widely different clinical phenotypes.
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